Director’s Major Stock Sale Shakes Up Glaukos!

New insider activity at Glaukos ( (GKOS) ) has taken place on December 11, 2025.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential Director Gilbert Kliman has recently sold 5,000 shares of Glaukos stock, amounting to a total transaction value of $536,350. Recent Updates on GKOS stock In the last 24 hours, Glaukos has seen positive developments as Citi and Needham both raised their price targets for the company. Citi increased its target due to an optimistic outlook for the medical technology sector, expecting a rebound driven by company catalysts and sector rotation. Needham’s adjustment was influenced by discussions with doctors who are optimistic about Glaukos’s products, particularly Epioxa, which could enhance treatment capacity and drive near-term upside. These factors contribute to the belief that Glaukos is poised for growth, leading to increased price targets. Spark’s Take on GKOS Stock According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral. Glaukos’s strong sales growth and strategic product developments are significant positives. However, profitability challenges and valuation concerns weigh on the overall score. The technical indicators suggest bullish momentum, but caution is advised due to overbought signals. To see Spark’s full report on GKOS stock, click here. More about Glaukos YTD Price Performance: -27.37% Average Trading Volume: 1,137,361 Technical Sentiment Signal: Buy Current Market Cap: $6.14B